Post-marketing Study Focused on Evaluating I+Med's DayDrop for Improving Signs and Symptoms of Mild/Moderate Dry Eye

Inclusion Criteria: * Patients of both sexes over 18 years of age. * Patients presenting symptoms of dryness and ocular irritation with an OSDI score ≥13 and ≤22. * Ability to self-administer the drops. * Ability to understand the Patient Information Sheet and sign the Informed Consent. * Willingness and sufficient ability, as judged by the investigator, to respond to the questionnaires included in the study. Exclusion Criteria: * Pregnant women or those in the breastfeeding period. * Known allergy or hypersensitivity to hyaluronic acid or any other ingredient in the product being studied. * Patients who have undergone previous ocular surgery or experienced ocular trauma in the year prior to the start of the study. * Severe dry eye diagnosis. * Presence of inflammatory ocular surface pathology or anterior segment disease, or diagnosed with glaucoma. * Use of parasympathomimetic or antipsychotic medications. * Previous cataract surgery. * Systemic corticosteroid treatment or topical treatment with any ophthalmic medication, except artificial tears, in the week before the start of the study. * Sjögren's syndrome. * Stevens-Johnson syndrome. * History of allergic conjunctivitis.